Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities (2022 - 2024)

Insight Molecular Diagnostics' Preferred Stock Liabilities history spans 3 years, with the latest figure at $5.3 million for Q1 2024.

  • On a quarterly basis, Preferred Stock Liabilities fell 3.62% to $5.3 million in Q1 2024 year-over-year; TTM through Mar 2024 was $5.3 million, a 3.62% decrease, with the full-year FY2023 number at $5.1 million, down 3.32% from a year prior.
  • Preferred Stock Liabilities hit $5.3 million in Q1 2024 for Insight Molecular Diagnostics, up from $5.1 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for IMDX hit a ceiling of $5.5 million in Q1 2023 and a floor of $4.7 million in Q2 2023.
  • Historically, Preferred Stock Liabilities has averaged $5.1 million across 3 years, with a median of $5.1 million in 2022.
  • Biggest five-year swings in Preferred Stock Liabilities: decreased 2.66% in 2023 and later decreased 3.62% in 2024.
  • Tracing IMDX's Preferred Stock Liabilities over 3 years: stood at $5.3 million in 2022, then decreased by 3.32% to $5.1 million in 2023, then grew by 4.02% to $5.3 million in 2024.
  • Business Quant data shows Preferred Stock Liabilities for IMDX at $5.3 million in Q1 2024, $5.1 million in Q4 2023, and $4.9 million in Q3 2023.